Compare Amplify Transformational Data Sharing ETF (BLOK) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs Inovio Pharmaceuticals Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $61.53, while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BLOK | INO | |
|---|---|---|
52-Week High | $74.10 | $2.87 |
52-Week Low | $47.36 | $1.05 |
Market Cap | — | $95.85M |
Sector | — | Health |
Enterprise Value | — | $66.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.81, down 2.95% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights the fund's diversified blockchain economy exposure, including bitcoin miners and enterprise adopters. The company announced a $0.08 dividend scheduled for June 2026, providing income potential for shareholders.
Outlook remains cautious with technical indicators signaling bearish momentum. The fund's increased bitcoin exposure to approximately 40% introduces volatility risks, though diversification across AI infrastructure and payment processors offers some stability. Investment opportunity exists for long-term investors seeking blockchain economy exposure, but near-term performance depends heavily on crypto market direction and AI infrastructure growth.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
